What are Janus Kinase Inhibitor [EPC] drugs?

Janus Kinase Inhibitor [EPC] drugs are pharmacologic agents that share a common mechanism (typically targeting Tyrosine-protein kinase JAK2). 11 are currently marketed, with 2 more in clinical development.

What are the marketed Janus Kinase Inhibitor [EPC] drugs?

Marketed Janus Kinase Inhibitor [EPC] drugs include Olumiant, In open-label phase: treatment with tofacitinib, Cibinqo, Abrocitinib 100 mg, Cibinqo, BARICITINIB.

Janus Kinase Inhibitor [EPC]

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

11 marketed 2 in Phase 3

This page covers all Janus Kinase Inhibitor [EPC] drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Tyrosine-protein kinase JAK2, Janus kinase 1 (JAK1), Janus kinase 3 (JAK3), and tyrosine kinase 2 (TYK2), Tyrosine-protein kinase JAK1.

Targets

Tyrosine-protein kinase JAK2 · Janus kinase 1 (JAK1), Janus kinase 3 (JAK3), and tyrosine kinase 2 (TYK2) · Tyrosine-protein kinase JAK1 · JAK1 · JAK1 and JAK3 · JAK1 and JAK2 enzymes · JAK1, JAK2, JAK3, TYK2

Marketed (11)

Olumiant · Eli Lilly · Immunology · 1200
In open-label phase: treatment with tofacitinib · Pfizer · Immunology · 1087
Cibinqo · Pfizer · Immunology · 284
Cibinqo works by blocking the activity of the JAK1 enzyme, which plays a key role in the inflammatory response.
Abrocitinib 100 mg · Pfizer · Immunology · 284
Cibinqo · Pfizer · Immunology · 284
Cibinqo works by blocking the JAK1 enzyme, which helps reduce inflammation in the body.
BARICITINIB
Tofacitinib (Xeljanz) · Pfizer · Immunology
Chronic- PF-06480605 150 mg SC Q4W · Pfizer · Immunology
Janus Kinase Inhibitor · Peking Union Medical College Hospital · Immunology
Janus Kinase Inhibitors block JAK proteins, which are intracellular signaling enzymes that transmit inflammatory and immune signals from cell surface receptors to the nucleus.
ABROCITINIB
CIBINQO works by reversibly inhibiting JAK1, blocking ATP binding and showing selectivity over other JAKs.
Corectim · Japan Tobacco · Immunology
Delgocitinib works by blocking the JAK2 enzyme, which plays a key role in the immune system's inflammatory response.

Phase 3 pipeline (2)

CXL · Pfizer · Rheumatology
CXL is a small molecule that inhibits the activity of a specific enzyme.
DR-102 · Teva Branded Pharmaceutical Products R&D, Inc. · Rheumatology
DR-102 is a small molecule that inhibits the activity of a specific enzyme.

Patent intelligence

janus kinase inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates